Kyle Knouse’s Post

#GSK acquired #Elsie Biotechnologies for $50 M after an 11-month research collaboration, turning a non-exclusive license into full ownership, toward its efforts to advance oligonucleotide drug discovery. Enhanced Capabilities: The acquisition combines Elsie’s oligonucleotide discovery #platform with GSK’s internal expertise, aiming to design treatments for difficult-to-treat diseases with large patient populations. Integration with AI: GSK plans to integrate data from Elsie's platform with its #AI and machine learning capabilities to develop predictive models for future oligonucleotide drug designs. Pipeline Expansion: The acquisition strengthens GSK’s oligonucleotide pipeline, including potential treatments for chronic hepatitis B and steatotic liver disease. GSK’s key candidate #bepirovirsen is expected to deliver Phase 3 data by 2026. Detailed News: https://lnkd.in/gQeGg2VR Stay up-to-date on the latest trends and news in the pharmaceutical industry. Follow our page for more insights: https://lnkd.in/de5zNWmK #BiotechNews #PharmaInnovation #Oligonucleotides #AIinHealthcare #DrugDiscovery #HealthcareInnovation #GSK #Biotechnology #LifeSciences #PharmaAcquisition #RASLSS

|| Pharma Fusion Series 1.8 || 🌟 Vertex Pharmaceuticals's Mega $4.9B Deal with Alpine Immune Sciences, Inc. Signals Immunotherapy Surge 💼💥🚀 Vertex Pharmaceuticals has acquired Alpine Immune Sciences, Inc., for $4.9 billion. This strategic move aims to accelerate the development and potential commercialization of povetacicept, a promising treatment for IgA nephropathy and other serious autoimmune diseases. 💼💡 The acquisition enhances Vertex's capabilities with Alpine's expertise in protein engineering and immunotherapy, signaling a notable advancement in protein-based immunotherapies. This acquisition has the potential to significantly impact the future of immunotherapy and the treatment of serious autoimmune conditions, ultimately benefiting patients in need. 🌟🩺 #PharmaceuticalInnovation #VertexPharmaceuticals #AlpineImmuneSciences #IgANephropathy #AutoimmuneDisease #ImmunoTherapy #acquisition #merger #pharmanews #information #povetaciept #proteinengineering #niper #dopm #pharmamba #pharmaprofessionals #FiercePharma ##reuterseventspharma #Reuters

Elevating #DrugDevelopment with Precision-Crafted Cyclized Peptides At Mimotopes, we're driven by the belief that the next breakthrough in healthcare can come from anywhere – and anyone. That's why we're dedicated to empowering researchers and developers with the tools they need to transform innovative concepts into life-changing treatments. Among the myriad of tools in the pharmaceutical toolkit, #cyclizedpeptides hold a special place. Their remarkable stability, high specificity, and reduced toxicity make them pivotal in the development of next-generation therapeutics. From immunosuppressants like #Cyclosporine to diabetes treatments such as #Exenatide, cyclized peptides are forging new paths in drug development. 💡 Why Cyclized Peptides? - Stability & Specificity: Their cyclic structure offers enhanced stability and specificity, crucial for targeting complex biological processes. - Versatility: From cancer to autoimmune diseases and beyond, cyclized peptides are versatile tools in addressing a broad spectrum of therapeutic needs. - Innovation Potential: They represent a frontier of innovation, especially in areas where traditional therapies fall short. At Mimotopes, we stand ready to support your journey from concept to clinic. Our commitment is to provide: - Custom Synthesis: Tailored cyclized peptides with the modifications and purity levels your research demands. - Unmatched Quality: Each peptide is synthesized with an unwavering focus on achieving the highest purity and bioactivity. - Collaborative Support: We don't just supply peptides; we partner with you, offering expertise to help navigate the complexities of drug development. Whether you're exploring novel treatments for chronic diseases or searching for the next breakthrough in immunotherapy, Mimotopes is your ally. Let's push the boundaries of what's possible together. Mimotopes #DrugDevelopment #CyclizedPeptides #Innovation #PharmaceuticalResearch

50% of clinical failures are attributed to a lack of efficacy. Reasons for this often go back to the earliest phases of R&D: decisions on the target and the clinical positioning do not only set the foundations for development but also largely determine success rates. Today, stakeholders lack tools to systematically assess target efficacy and safety with human evidence. Our mission at Pheiron is to change that. We use #AI and #populationgenetics to find routes through early R&D that have a higher likelihood of clinical success: de-risked targets, linked biomarkers and aligned clinical phenotypes. Read more about what we’re building here: https://lnkd.in/e6kubYvv #phenotyping #geneticevidence #AI #populationgenetics #predictiveutility

I sat down with C&EN during #JPM2024 – the premier week for life science dealmaking – to discuss our pioneering work in targeted protein degradation. We explored the importance of strategic partnerships in accelerating our progress in this new modality, which could reshape what is possible for patients in need. At Astellas Pharma, we are combining our capabilities with the expertise of ambitious innovators to advance the development of targeted protein degraders capable of effectively treating more diseases in more patients. You can read the full article here: http://bit.ly/48BcGV2 #Changingtomorrow #ScienceFirstForPatients

Thoughts on this? >> After tough rightsizing, Biogen looks to newer rare diseases to broaden lens >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #competitivemarketing #biotech #pharmaceutical

𝗕𝗲𝘃𝗮𝗰𝗶𝘇𝘂𝗺𝗮𝗯 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report comprehensively covers the development of the Bevacizumab industry chain, examining the market status in Cancer (Avastin (bevacizumab), Mvasi (bevacizumab-awwb)) and Eye Disease (Avastin (bevacizumab), Mvasi (bevacizumab-awwb)) applications. It profiles key enterprises across developed and developing markets, analyzing cutting-edge technologies, patents, hot applications, and market trends within Bevacizumab. Regionally, North America and Europe are experiencing consistent growth driven by government initiatives and increasing consumer awareness. In Asia-Pacific, particularly in China, the Bevacizumab market leads globally due to strong domestic demand, supportive policies, and a robust manufacturing infrastructure. The report segments the market by Type and Application, providing accurate calculations and forecasts for consumption value in terms of volume and value from 2024 to 2031, offering insights into growth trends across these segments. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗕𝗲𝘃𝗮𝗰𝗶𝘇𝘂𝗺𝗮𝗯 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dE-spXqA *𝗕𝘆 𝗧𝘆𝗽𝗲: Avastin (bevacizumab), Mvasi (bevacizumab-awwb) *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Cancer, Eye Diease *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Genentech, Amgen, Aark Pharmaceuticals, Beacon Pharmaceuticals PLC, Balaji Medical Services Limited, Mylan #bevacizumab #cancertherapy #anticancerdrug #biologicaltherapy #oncology #cancerresearch #vascularinhibitor #cancermedicine #healthcare #medicaltreatment #angiogenesisinhibitor #biopharmaceutical #monoclonalantibody #healthcareinnovation #clinicaltrials #cancerdrugs #precisionmedicine #drugdevelopment #pharmaceuticals #targetedtherapy #antivasculartherapy #molecularmedicine #biotechnology #tumorinhibitor #medicalresearch #cancercare #healthtech

#Didyouknow On May 29, 2024, the FDA notified selected participants of their acceptance into the Support for #clinicaltrials Advancing #Rarediseases Therapeutics #START Pilot Program. Read more: https://lnkd.in/eFNrXnCV 𝐁𝐚𝐜𝐤𝐠𝐫𝐨𝐮𝐧𝐝 The FDA launched the START program in Sep 2023 to [...] 𝘩𝘦𝘭𝘱 𝘧𝘶𝘳𝘵𝘩𝘦𝘳 𝘢𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘦 𝘵𝘩𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘰𝘷𝘦𝘭 𝘥𝘳𝘶𝘨 𝘢𝘯𝘥 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘧𝘰𝘳 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘰𝘧 𝘳𝘢𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴.[...] The participants of the program will benefit from increased communication with FDA officials to receive timely advice for addressing their #clinicaldevelopment program-specific needs, including #clinicalstudydesign, choice of control group, fine-tuning the choice of #patientpopulation, leveraging nonclinical information, and product characterization. The eligibility criteria are the following: 👉 𝐉𝐨𝐢𝐧𝐭 𝐂𝐁𝐄𝐑 𝐚𝐧𝐝 𝐂𝐃𝐄𝐑 𝐄𝐥𝐢𝐠𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐂𝐫𝐢𝐭𝐞𝐫𝐢𝐚 The program is open to sponsors 📌of products currently in #clinicaltrials under an active investigational new drug application #IND submitted in or converted to Electronic #CommonTechnicalDocument #eCTD format 📌who have demonstrated substantial effort to ensure that Chemistry, Manufacturing, and Controls #CMC development aligns with clinical development. 👉 𝐂𝐁𝐄𝐑-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐄𝐥𝐢𝐠𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐂𝐫𝐢𝐭𝐞𝐫𝐢𝐚: Eligible products must be a gene or #cellulartherapy intended to address an unmet medical need as a treatment for a serious rare disease or condition, which is likely to lead to significant disability or death within the first decade of life. 👉 𝐂𝐃𝐄𝐑-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐄𝐥𝐢𝐠𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐂𝐫𝐢𝐭𝐞𝐫𝐢𝐚: Products must be intended to treat rare #neurodegenerative conditions, including those of rare genetic #metabolic etiology. #pharma #pharmaindustry #biotech #fdacompliance #regulatoryaffairs